RVTY Stock Analysis — Revvity
Sector: Healthcare
AI Verdict
Revvity trades at 18.0x next year's earnings while analysts expect 57.7% EPS growth — that's cheap for the growth on offer if its recurring revenue moat holds up, but the high RSI makes a near-term pullback likely.
Competitive Moat
Revvity specializes in life sciences and diagnostics, with a defensible position built on proprietary assay technologies and a large installed base in labs and hospitals. Its recurring consumables revenue and integration into clinical workflows create switching costs that protect market share.
Summary
Revvity is drawing attention for its expected 57.7% jump in earnings over the next year, far outpacing its sector.
Where It Stands
The stock is up 11.32% over the past year, trades at 18.0x next year's earnings (below the healthcare median of 22x), and its RSI of 69.6 signals elevated risk of a pullback.
Key Metrics
- RSI: 69.6 — Near Overbought
- Trailing P/E: 28.4x
- Forward P/E: 18.0x
- PEG Ratio: 0.49
- Earnings Growth: +0.6%
- Revenue Growth: +0.0%
- Market Cap: $12.6B
- Dividend Yield: 0.00%
- 1-Year Return: 11.32%
- 52-Week High: $118.30
- 52-Week Low: $81.22
Analyst Consensus
13 Buy · 12 Hold · 0 Sell (25 analysts)
Bull Case
With analysts forecasting 57.7% EPS growth and a forward P/E of just 18.0x, you're paying a low price for unusually high expected profit gains.
Bear Case
An RSI of 69.6 means the stock is at elevated risk of a technical pullback, and a drop back to a sector-median 22x P/E would erase the current valuation discount.
Catalyst to Watch
Watch for quarterly earnings — if EPS growth meets or beats the 57.7% forecast, the valuation case strengthens.